Objective:To automatically synthesize Al 18F-1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid (NOTA)-fibroblast activation protein inhibitor (FAPI)-04, perform PET/CT imaging in vivo, and evaluate its diagnostic efficacy on tumors. Methods:Al 18F-NOTA-FAPI-04 was produced in All-in-one automatic synthesis module and its quality control was conducted by high performance liquid chromatography (HPLC) equipped with a radioactive detector. Al 18F-NOTA-FAPI-04 PET/CT imaging was performed in normal BALB/c mice ( n=3) and 4T1 breast cancer models ( n=3) to determine its biodistribution. Then Al 18F-NOTA-FAPI-04 and 18F-FDG PET/CT imaging were performed in a hepatocellular carcinoma patient (male, 51 years old). Results:The synthesis time of Al 18F-NOTA-FAPI-04 was about 35 min, and the radiochemical yield was (25.2±1.9)% (attenuation correction, n=3). The product was colorless transparent solution with pH value of 7.0-7.5, and the specific activity was (46.11±3.07) GBq/μmol (attenuation correction, n=3). The radiochemical purity was above 99.0% and was still above 98.0% at room temperature after 6 h. PET/CT imaging in mice showed that physiological uptake of Al 18F-NOTA-FAPI-04 was mainly in biliary system and bladder, and Al 18F-NOTA-FAPI-04 highly concentrated in tumor xenografts. PET/CT imaging in the patient showed that Al 18F-NOTA-FAPI-04 obtained high tumor background ratio (TBR) values of 4.1, 8.9, 5.4, 4.8, 2.2 in parasternal lymph nodes, anterior diaphragmatic lymph nodes, hilar lymph nodes, pancreaticoduodenal ligament lymph nodes, abdominal aortic lymph nodes, respectively, while TBR values were 1.0, 2.8, 5.0, 2.1, 1.1 by 18F-FDG. Conclusions:Al 18F-NOTA-FAPI-04 can be synthesized with short time, high radiochemical yield and good stability using All-in-one module. Al 18F-NOTA-FAPI-04 PET/CT imaging has high contrast and excellent diagnostic efficacy on tumors.

Objective:The investigation and research on the application status of Hepatic Venous Pressure Gradient (HVPG) is very important to understand the real situation and future development of this technology in China.Methods:This study comprehensively investigated the basic situation of HVPG technology in China, including hospital distribution, hospital level, annual number of cases, catheters used, average cost, indications and existing problems.Results:According to the survey, there were 70 hospitals in China carrying out HVPG technology in 2021, distributed in 28 provinces (autonomous regions and municipalities directly under the central Government). A total of 4 398 cases of HVPG were performed in all the surveyed hospitals in 2021, of which 2 291 cases (52.1%) were tested by HVPG alone. The average cost of HVPG detection was (5 617.2±2 079.4) yuan. 96.3% of the teams completed HVPG detection with balloon method, and most of the teams used thrombectomy balloon catheter (80.3%).Conclusion:Through this investigation, the status of domestic clinical application of HVPG has been clarified, and it has been confirmed that many domestic medical institutions have mastered this technology, but it still needs to continue to promote and popularize HVPG technology in the future.

Objective To evaluate the effect of local flaps on repair of defects after surgical removal of nasal skin tumors.Methods A total of 65 patients with nasal skin tumors were enrolled from Department of Dermatology,People's Hospital of Xinjiang Uygur Autonomous Region between March 2015 and August 2016,and subjected to surgical removal of the nasal skin tumors.According to the location,size,shape and surrounding skin of the nasal defects,nasolabial fold flaps,modified rhomboid flaps,bilobed flaps or frontal nasal flaps were chosen to repair skin and soft tissue defects.Results Of the 65 patients with nasal skin tumors,38 had basal cell carcinoma,20 pigmented nevus,5 keratoacanthoma,and 2 had squamous cell carcinoma.The lengths of the defects after resection were all below 2.5 cm.Nasolabial fold flaps were used in 32 cases,modified rhomboid flaps in 16,bilobed flaps in 12,and frontal nasal flaps in 5.All the flaps survived after the surgery,and no obvious deformation of the nose was observed.No recurrence was observed during 1 year of follow-up.Conclusion For skin defects with the length ≤ 2.5 cm after resection of nasal skin tumors,nasolabial fold flaps,modified rhomboid flaps,bilobed flaps and frontal nasal flaps can be used to repair wounds,with satisfactory efficacy.

Overexpressing of ATP-binding cassette (ABC) transporters is the essential cause of multidrug resistance (MDR), which is a significant hurdle to the success of chemotherapy in many cancers. Therefore, inhibiting the activity of ABC transporters may be a logical approach to circumvent MDR. Olmutinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which has been approved in South Korea for advanced EGFR T790M-positive non-small cell lung cancer (NSCLC). Here, we found that olmutinib significantly increased the sensitivity of chemotherapy drug in ABCG2-overexpressing cells. Furthermore, olmutinib could also increase the retention of doxorubicin (DOX) and rhodamine 123 (Rho 123) in ABC transporter subfamily G member 2 (ABCG2)-overexpressing cells. In addition, olmutinib was found to stimulate ATPase activity and inhibit photolabeling of ABCG2 with [I]-iodoarylazidoprazosin (IAAP). However, olmutinib neither altered ABCG2 expression at protein and mRNA levels nor blocked EGFR, Her-2 downstream signaling of AKT and ERK. Importantly, olmutinib enhanced the efficacy of topotecan on the inhibition of S1-MI-80 cell xenograft growth. All the results suggest that olmutinib reverses ABCG2-mediated MDR by binding to ATP bind site of ABCG2 and increasing intracellular chemotherapeutic drug accumulation. Our findings encouraged to further clinical investigation on combination therapy of olmutinib with conventional chemotherapeutic drugs in ABCG2-overexpressing cancer patients.

Objective To investigate the level and significance of serum cystatin C in the patients with hypertension compli-cating left ventricular hypertrophy and atherosclerosis.Methods A total of 300 patients with essential hypertension in the cardiolo-gy department of Taizhou Municipal Central Hospital from January 2013 to December 2016 were prospectively selected as the study subjects and divided into the group A(hypertensive group,140 cases),group B[hypertension+carotid artery intima-media thickness (IM T)thickening group,75 cases],group C(hypertension+ left ventricular hypertrophy group,45 cases)and group D(hyperten-sion+carotid IMT thickening+left ventricular hypertrophy group,40 cases)according to whether complicating left ventricular hy-pertrophy and carotid atherosclerosis.The patient′s clinical data and serum cystatin C levels were collected and performed the com-parison.Results The level of LDL in the group B and D was higher than that in the group A and group C(P<0.05);the serum cystatin level in the group B,C and D was higher than that in the group A(P<0.05).The serum cystatin level in the group D was higher than that in the group B and C(P<0.05).There was positive correlation between carotid IMT with low-density lipoprotein, creatinine and cystatin C(P<0.05).The serum cystatin C level was positively correlated with left ventricular mass index(LVMI), left ventricular posterior wall thickness(LVPWT)and interval thickness(IVST)(P<0.05).Conclusion The serum cystatin C lev-el in the patients with hypertension is associated with left ventricular hypertrophy and atherosclerosis occurrence.

Objective To investigate the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of coronary heart disease .Methods 80 patients with coronary heart disease were selected as the research subjects.80 patients were randomly divided into two groups .The observation group was given atorvastatin combined with trimetazidine .The control group was treated with trimetazidine .The clinical efficacy ,serum lipids levels ,hemody-namic changes and adverse reaction were observed and evaluated .Results The observation group had markedly effective in 31 cases,effective in 7 cases,ineffective in all cases ,the total effective rate was 95.0％,which was signifi-cantly higher than 77.5％of the control group(effective in 10 cases,ineffective in 9 cases,χ2 =6.818,P<0.05). The levels of TG,TC,LDL-C,HDL-C in the observation group were (1.2 ±0.2) mmol/L,(2.4 ±1.0) mmol/L, (1.5 ±0.0) mmol/L,(0.7 ±0.1) mmol/L,which in the control group were (1.6 ±0.1) mmol/L,(3.59 ± 1.2)mmol/L,(2.2 ±0.1)mmol/L,(0.9 ±0.2)mmol/L,the serum lipids levels between the two groups had statisti-cally significant differences (t =5.41,3.47,4.87,2.05,P<0.05).The whole blood viscosity (low cut),blood viscosity(high cut),plasma viscosity of the observation group were (6.98 ±0.23)mPa· s,(5.07 ±0.13)mPa· s, (1.21 ±0.12) mPa· s,which were significantly lower than those of the control group [(9.01 ±0.21) mPa· s, (6.01 ±0.01)mPa· s,(1.54 ±0.21)mPa· s,t=5.24,4.47,5.44,all P<0.05].In the observation group,0 case of dizziness,1 case of skin rash,nausea and vomiting in 1 case,the incidence rate of adverse reactions was 5.0％.In the control group,2 cases of dizziness,3 cases of skin rash,nausea and vomiting in 4 cases,the incidence rate of adverse reaction was 22.5％,there was no statistically significant difference between the two groups (χ2 =0.867,P>0.05).Conclusion The clinical curative effect of atorvastatin combined with trimetazidine in the treatment of coro -nary heart disease is accurate ,it can reduce blood fat,improve the abnormal blood rheology ,and it is safe,with less adverse reactions ,which is worthy of application and promotion .

Objective To investigate the clinical efficacy of benazepril combined with amlodipine in the treatment of essential hypertension.Methods From January 2016 to January 2017,90 patients with coronary heart disease in Taizhou Central Hospital were selected in the study,and they were randomly divided into three groups,with 30 cases in each group.The observation group(A group)was treated with benazepril combined with amlodipine,the control group (B group )was treated with benazepril,and the control group (C group)was treated with amlodipine. The clinical efficacy,blood pressure,blood lipid changes,blood glucose changes before and after treatment in the three groups were compared.Results The total effective rate of A group was 96.367%,which of B group was 66.67%, which of C group was 70.00%,and the clinical efficacy among the three groups had statistically significant difference (χ2＝11.96,P＜0.05).Before treatment,the systolic blood pressure(SBP)and diastolic blood pressure(DBP)of the three groups had no statistically significant differences(F＝0.98,0.85,all P＞0.05).After treatment,the SBP, DBP of the three groups were significantly lower than those before treatment(t＝5.68,7.21,3.52,3.16,3.64,3.16, all P＜0.05),the SBP and DBP of A group were significantly lower than those of B group and C group(F＝6.24, 3.27,all P＜0.05).After treatment,only the TC,TG,HDL－C levels of A group had statistically significant differ-ences compared with those before treatment(t＝5.29,6.28,2.31,all P＜0.05),and the TC,TG levels of A group were significantly lower than those of B group and C group(F＝3.18,2.86,all P＜0.05),while the HDL－C level of A group increased significantly compared with that of B group and C group(F＝3.78,P＜0.05 ).Before treatment, the FPG,FINS among the three groups had no statistically significant differences (F＝0.85,0.95,all P＞0.05 ). After treatment,only the FPG,FINS of A group had statistically significant differences compared with those before treatment(t＝5.14,3.65,all P＜0.05),and the FPG,FINS of A group were significantly lower than those of B group and C group(F＝5.27,2.86,all P＜0.05).The adverse reaction rate in A group was 6.67%,which in B group was 30.00%,which in group C was 26.67%,and there was no statistically significant difference among the three groups (χ2＝1.72,P＞0.05).Conclusion Benazepril combined with amlodipine in the treatment of essential hypertension is effective,safe,and has less adverse reactions.

Objective To study the distribution of bacterium extended spectrum beta lactamases (ESBLs) in sputum samples from patients with lower respiratory tract infection in Panzhihua Hospital of Integrated Traditional Chinese and Western Medicine . Methods A total of 512 strains of gram negative bacterium were isolated from sputum samples of patients with lower respiratory tract infection from January 2014to January 2016 ,standard disk diffusion method was used to detected ESBLs ,drug sensitivity was performed by K-B disk diffusion method .Distribution and drug resistant status of ESBLs bacterium were analyzed .Results Detec-tion rate of ESBLs bacteriumin cadre ward and ICU were higher than that in department of respiration ,and the difference was sta-tistical significant(P< 0 .01) .Among ESBLs bacterium isolated from department of respiration ,Escherichia coli accounted for 37 .5% ,Enterobacter cloacae accounted for 25 .8% .Among ESBLs bacterium isolated from cadre ward ,Escherichia coli accounted for 58 .2% ,Enterobacter cloacae accounted for 45 .5% .The resistant rate of gram negative bacterium producing ESBLs to trime-thoprim was lowest .Conclusion It′s important to understand the distribution and drug resistant status of gram negative bacterium , so as to provide the basis for rational use of antibiotics .

BACKGROUND: Human lower limb system under different motion statuses exhibits great difference in terms of kinetic characteristics and joint deformation magnitude. Total hip replacement has been shown to be the best method to solve the severe illness of hip joints today. A good understanding of the responses of human lower limb system, in particular the knee joint, following total hip replacement is significant for rehabilitation training of patients.OBJECTIVE: To analyze the effects of total hip replacement on knee joint deformation during motions by comparing the data collected from a patient who underwent total hip replacement 19 months ago and a healthy control subject under the same testing environment and method.METHODS: The patient was measured through the use of Optotrak Certus motion capture system (Northern Digital Inc.,California), and simultaneously measurements were performed in a healthy control subject presenting with similar body weight and body mass. Measurement indices included step length, step frequency, joint corner, and joint displacement curves. Speed and acceleration of each joint were calculated based on measured data.RESULTS AND CONCLUSION: Following total hip replacement, the structure of natural hip joint was destroyed. Although the gait did not change greatly, experimental data showed that knee joint deformed more greatly than normal gait, indicating the self-accommodation of human body, i.e., increasing the loading and deformation magnitude of knee joints can avoid the injuries caused by hip joint surgery.

In order to investigate the ability of PEG-PEI copolymers as gene carriers for delivery of VEGF165. A series of PEG-PEI copolymers with different PEG grafting was prepared and the cytotoxicity was evaluated. Simultaneously,the VEGF165 gene segment with HindⅢ and BamHⅠ site was obtained by PCR, which was cloned into pEGFP-C1. PEG-PEI/ pEGFP-VEGF165 complexes were formed by self-assembly and transfected HUVEc. Transfection efficiency was evaluated by measuring the percentage of cells expressing green fluorecensce protein. The VEGF expression was detected by ELISA, RT-PCR, and the effect of transfection on growth of endothelial cell was evaluated by MTT. The results suggested that the formation of PEG-PEI copolymers could help to reduce the cytotoxicity of PEI. After transfection, the strong expression of green fluorescence protein was observed by fluorescence microscopy. The transfection efficiency was influenced by the number of PEG side chains and N/P ratio. Of all copolymers tested, the transfection efficiency of PEG-PEI(5-25-1) at N/P = 30 reached a maximum, which was much higher than that of PEI. The expression of VEGF protein and mRNA increased significantly, and HUVEc proliferation was accelerated after transfection.These results indicates PEG-PEI copolymers can be used as effective gene carriers for delivery of pEGFP-VEGF165 gene.